SCHEMBL10003464

SCHEMBL10003464

CCc1nc2c(cc1-c1ccccc1F)c(OCC(F)(F)F)c(C(=O)O)n2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIA2 P42262 2/20 0.39
▸ GRIA4 P48058 2/20 0.39
▸ ADORA2A P29274 3/20 0.36
▸ ADORA1 P30542 3/20 0.36
▸ ADORA3 P0DMS8 2/20 0.36
▸ ADORA2B P29275 1/20 0.36
▸ LTB4R Q15722 1/20 0.36
▸ DHODH Q02127 1/20 0.35
▸ HCRTR1 O43613 1/20 0.34
▸ HCRTR2 O43614 1/20 0.34
▸ EGLN1 Q9GZT9 1/20 0.33
▸ SCN9A Q15858 3/20 0.33
▸ UGCG Q16739 1/20 0.33
▸ RXRA P19793 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10004215 0.90 HPGD (0.42) ADORA2AADORA1ADORA3ADORA2BHCRTR1
SCHEMBL10003096 0.89 GRIA2 (0.35) GRIA2GRIA4HCRTR1HCRTR2SCN9A
SCHEMBL10003039 0.89 SCN9A (0.41) GRIA2GRIA4ADORA1ADORA3DHODH
SCHEMBL10003734 0.86 CYP1A2 (0.35) ADORA3HCRTR1HCRTR2SCN9AUGCG
SCHEMBL10002905 0.85 GRIA2 (0.38) GRIA2GRIA4SCN9ARXRAALDH1A1
SCHEMBL10003319 0.85 GRIA2 (0.41) GRIA2GRIA4DHODHHCRTR1HCRTR2
SCHEMBL10003113 0.85 CCKAR (0.37) GRIA2GRIA4SCN9A
SCHEMBL10003659 0.84 RXRA (0.35) GRIA2GRIA4DHODHSCN9ARXRA
SCHEMBL10003383 0.83 ALPI (0.35) SCN9ARXRAL3MBTL1
SCHEMBL10003244 0.83 PTPN11 (0.39) LTB4RSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH GRIA2 3298/4885GRIA4 2962/4885ADORA2A 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback